Trails Edge Capital Partners LP Purchases New Position in Century Therapeutics, Inc. $IPSC

Trails Edge Capital Partners LP acquired a new position in Century Therapeutics, Inc. (NASDAQ:IPSC) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,134,969 shares of the company’s stock, valued at approximately $10,130,674,000. Century Therapeutics comprises approximately 1.6% of Trails Edge Capital Partners LP’s holdings, making the stock its 25th largest position. Trails Edge Capital Partners LP owned 2.29% of Century Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after acquiring an additional 34,466 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after purchasing an additional 86,875 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Century Therapeutics by 26.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock worth $86,000 after purchasing an additional 38,052 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Century Therapeutics by 101.2% during the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after purchasing an additional 142,953 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Century Therapeutics in the 2nd quarter valued at $25,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Price Performance

NASDAQ:IPSC opened at $2.17 on Wednesday. Century Therapeutics, Inc. has a one year low of $0.44 and a one year high of $3.04. The company has a fifty day moving average price of $2.17 and a 200 day moving average price of $2.22. The stock has a market cap of $392.92 million, a P/E ratio of -2.33 and a beta of 1.57.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.06). As a group, equities research analysts anticipate that Century Therapeutics, Inc. will post -0.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Mizuho started coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They set an “outperform” rating and a $8.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research report on Thursday, July 2nd. Finally, Wall Street Zen downgraded Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $4.75.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.